P-21 and PE-22-28 are both sold as nootropic-class research peptides, and they have almost nothing in common except a named target. That last part is what distinguishes them from most of the neuropeptide catalogue. One is a fragment of a neurotrophic factor, modified until it barely counts as a peptide; the other is a fragment of a channel-modulating propeptide. Each has a mechanism specific enough to be tested with a positive control and a blocker, which is more than Selank or Semax can offer.
P-21: a neurotrophic factor, reduced to four residues
Ciliary neurotrophic factor is a 200-residue cytokine associated with the survival and differentiation of neurons. It cannot cross membranes, is cleared rapidly, and its receptor is broadly expressed — three reasons the full protein is a poor research tool. P-21, also written P021, is a tetrapeptide taken from a short region of it, N-terminally acetylated, C-terminally amidated, and carrying an adamantane group on one residue.
The adamantane is the part worth noticing. It is a rigid cage of carbon, entirely non-peptide, attached to add bulk and lipophilicity and to resist degradation. The molecule that results is closer to a peptidomimetic than a peptide: two ends capped, a cage bolted on, and a core of four residues that carries whatever activity remains.
Does P-21 act at the CNTF receptor?
The proposal is that it does not, or not directly. The reported mechanism runs through increased expression of brain-derived neurotrophic factor, with the peptide described as a modulator rather than a receptor agonist. That is a downstream observation — BDNF went up — rather than a binding event, and the step between the tetrapeptide and the BDNF gene is the open question. A four-residue fragment of a 200-residue cytokine is not expected to reproduce the cytokine's receptor engagement, for the usual reason fragments do not inherit their parents' activities; if P-21 is active, it is probably by a route the parent does not use.
PE-22-28: seven residues from a channel blocker
Spadin is a 17-residue peptide released from the propeptide of sortilin, a sorting receptor. It was found to block TREK-1, a potassium channel that sets the resting membrane potential of neurons, and blocking TREK-1 was associated with rapid antidepressant-like activity in rodent models. PE-22-28 is residues 22 to 28 of the spadin sequence — seven residues that retain the channel-blocking activity with improved stability over the parent.
| P-21 | PE-22-28 | |
|---|---|---|
| Parent | Ciliary neurotrophic factor, 200 residues | Spadin, 17 residues |
| Length | 4 residues plus adamantane | 7 residues |
| Named target | Indirect: BDNF expression | Direct: TREK-1 potassium channel |
| Testable with a blocker? | Partly, downstream | Yes: channel current is the readout |
| Evidence base | Preclinical, one main group | Preclinical, one main group |
Why is a channel target easier to work with than a receptor target?
Because the readout is direct and electrical. A potassium channel either passes current or it does not, and patch-clamp electrophysiology measures that in real time on a single cell. A compound claimed to block TREK-1 can be tested by applying it and watching the current fall, with the channel expressed in a cell line that otherwise lacks it. There is no signalling cascade between the compound and the measurement, so the experiment is interpretable in a way a BDNF-expression readout is not. PE-22-28 is one of the few compounds in this catalogue whose primary claim can be checked on a bench in an afternoon.
Why does the rodent literature not transfer to a human claim?
Because it is rodent literature, and this site does not make human claims about anything it sells. Beyond that general point, TREK-1 biology has species differences, the behavioural models used for antidepressant-like activity in rodents are contested as predictors, and both compounds have primary literatures concentrated in single laboratories. None of that is a criticism of the work. It is a description of what kind of claim the evidence can support: a mechanism worth testing, in systems where the mechanism can be measured.
Handling the two
They could hardly be more different in the tube. P-21 is capped at both ends and carries a lipophilic cage; it is stable in solution far longer than an ordinary short peptide and dissolves poorly in water alone, so a small volume of organic solvent first is the standard route — and that solvent then belongs in the vehicle control. PE-22-28 is a plain seven-residue sequence with free termini and no modifications: water-soluble, and short-lived in any medium containing peptidases.
Which one needs the tighter timing?
PE-22-28, by a wide margin. An unmodified heptapeptide added to serum-containing medium is being degraded from both ends within minutes, so the concentration present at the readout depends on how long after addition the readout was taken. For an electrophysiology experiment this is manageable, because the measurement is immediate. For anything measured hours later it is a variable that has to be reported. P-21's caps and cage make it far more forgiving; its constraint is solubility rather than time.
What do both need that the catalogue can supply?
A lot certificate with identity confirmed by mass, because both are small enough that a synthesis error or a missing modification changes the molecule substantially and the name would not show it. For P-21 the adamantane group and both caps should be reflected in the observed mass; for PE-22-28 the mass should match the bare seven-residue sum. The identity panel is where a preparation of P-21 or PE-22-28 is confirmed to be the intended structure, and for compounds whose whole claim rests on a specific molecule engaging a specific target, that confirmation is the experiment's first control.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
